Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 288

1.

Monocyte cyclooxygenase-2 activity: a new therapeutic target for atherosclerosis?

Páramo JA, Rodríguez JA, Beloqui O, Orbe J.

Curr Drug Targets Cardiovasc Haematol Disord. 2005 Aug;5(4):303-11. Review.

PMID:
16101563
2.

[Cyclooxygenase-2: a new therapeutic target in atherosclerosis?].

Páramo JA, Beloqui O, Orbe J.

Med Clin (Barc). 2006 May 27;126(20):782-6. Review. Spanish.

PMID:
16792983
3.

Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability.

Cipollone F, Prontera C, Pini B, Marini M, Fazia M, De Cesare D, Iezzi A, Ucchino S, Boccoli G, Saba V, Chiarelli F, Cuccurullo F, Mezzetti A.

Circulation. 2001 Aug 21;104(8):921-7.

4.

Cyclooxygenase isoforms and atherosclerosis.

Belton O, Fitzgerald DJ.

Expert Rev Mol Med. 2003 Mar 7;5(9):1-18. Review.

PMID:
14987412
5.

Clinical pharmacology of selective COX-2 inhibitors.

Capone ML, Tacconelli S, Sciulli MG, Patrignani P.

Int J Immunopathol Pharmacol. 2003 May-Aug;16(2 Suppl):49-58. Review.

PMID:
14552704
6.

Clinical pharmacology of novel selective COX-2 inhibitors.

Tacconelli S, Capone ML, Patrignani P.

Curr Pharm Des. 2004;10(6):589-601. Review.

PMID:
14965322
7.

The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control.

Cipollone F, Iezzi A, Fazia M, Zucchelli M, Pini B, Cuccurullo C, De Cesare D, De Blasis G, Muraro R, Bei R, Chiarelli F, Schmidt AM, Cuccurullo F, Mezzetti A.

Circulation. 2003 Sep 2;108(9):1070-7. Epub 2003 Aug 11.

8.

Nonsteroidal anti-Inflammatory drugs and cardiovascular risk.

Howard PA, Delafontaine P.

J Am Coll Cardiol. 2004 Feb 18;43(4):519-25. Review.

9.

Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells.

Niederberger E, Manderscheid C, Grösch S, Schmidt H, Ehnert C, Geisslinger G.

Biochem Pharmacol. 2004 Jul 15;68(2):341-50.

PMID:
15194006
10.

Monocyte cyclooxygenase-2 overactivity: a new marker of subclinical atherosclerosis in asymptomatic subjects with cardiovascular risk factors?

Beloqui O, Páramo JA, Orbe J, Benito A, Colina I, Monasterio A, Díez J.

Eur Heart J. 2005 Jan;26(2):153-8. Epub 2004 Nov 30.

11.

Cardiovascular complications of non-steroidal anti-inflammatory drugs.

Fosslien E.

Ann Clin Lab Sci. 2005 Autumn;35(4):347-85. Review.

PMID:
16254252
12.
13.
14.

Anti-inflammatory drugs in the 21st century.

Rainsford KD.

Subcell Biochem. 2007;42:3-27. Review.

PMID:
17612044
15.

Cyclooxygenase-2 and prostaglandins in articular tissues.

Martel-Pelletier J, Pelletier JP, Fahmi H.

Semin Arthritis Rheum. 2003 Dec;33(3):155-67. Review.

PMID:
14671726
16.

Mechanisms underlying the cardiovascular effects of COX-inhibition: benefits and risks.

Martínez-González J, Badimon L.

Curr Pharm Des. 2007;13(22):2215-27. Review.

PMID:
17691994
17.

Selective COX-2 inhibitors and risk of myocardial infarction.

Krotz F, Schiele TM, Klauss V, Sohn HY.

J Vasc Res. 2005 Jul-Aug;42(4):312-24. Epub 2005 Jun 20. Review.

PMID:
15976506
18.

[Coxibs: highly selective cyclooxygenase-2 inhibitors. Part II. Side effects].

Burdan F, Korobowicz A.

Pol Merkur Lekarski. 2003 Apr;14(82):352-5. Review. Polish.

PMID:
12868201
19.

Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis.

Belton OA, Duffy A, Toomey S, Fitzgerald DJ.

Circulation. 2003 Dec 16;108(24):3017-23. Epub 2003 Nov 24.

20.

The role of COX-2 in acute pain and the use of selective COX-2 inhibitors for acute pain relief.

Lee Y, Rodriguez C, Dionne RA.

Curr Pharm Des. 2005;11(14):1737-55. Review.

PMID:
15892672
Items per page

Supplemental Content

Write to the Help Desk